Urticaria

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The relevance of the disease is due to its prevalence ― for acute urticaria up to 20% with predominance in the paediatric population, for chronic spontaneous urticaria up to 0.5–5% of the population. The course of the disease is characterised by unpredictability of prognosis of duration, effectiveness of standard therapy, serious impact on the quality of life of the patient, his relatives, the burden on health authorities. The lack of accurate understanding of the mechanisms of disease development, a wide range of pathogenetic treatment complicates the possibility of rapid achievement of drug remission. The clinical Recommendations contain up-to-date information on epidemiology, pathogenesis, clinical picture, differential diagnosis, possibilities of examination and stage treatment, including immunobiological therapy. The procedure of medical care, prophylaxis and dispensary observation, criteria for assessing the quality of patient management and supporting material, including questionnaires to assess the severity of the condition and the effectiveness of treatment are outlined. Clinical recommendations on urticaria are intended for practicing physicians of all specialities, students, teachers of medical schools, residents, postgraduates and researchers.

About the authors

Alexey A. Kubanov

State Research Center of Dermatovenerology and Cosmetology

Email: alex@cnikvi.ru
ORCID iD: 0000-0002-7625-0503

MD, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences

Russian Federation, Moscow

Alexander A. Baranov

Pediatrics and Child Health Research Institute of Petrovsky National Research Centre of Surgery; The First Sechenov Moscow State Medical University (Sechenov University)

Email: baranov@pediatr-russia.ru
ORCID iD: 0000-0003-3987-8112

MD, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences

Russian Federation, Moscow; Moscow

Leyla S. Namazova-Baranova

Pediatrics and Child Health Research Institute of Petrovsky National Research Centre of Surgery; The Russian National Research Medical University named after N.I. Pirogov

Email: leyla.s.namazova@gmail.com
ORCID iD: 0000-0002-2209-7531

MD, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences

Russian Federation, Moscow; Moscow

Elena R. Araviiskaia

Academician I.P. Pavlov First St. Petersburg State Medical University

Email: arelenar@mail.ru
ORCID iD: 0000-0002-6378-8582

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

Natalia G. Astafieva

Saratov State Medical University named after V.I. Razumovsky

Email: astang@mail.ru
ORCID iD: 0000-0002-7691-4584

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saratov

Vitaly T. Bazaev

North-Ossetian State Medical Academy

Email: v.bazaev@list.ru
ORCID iD: 0000-0003-0353-3147

MD, Dr. Sci. (Med.), Professor

Russian Federation, Vladikavkaz

Elena Y. Borzova

The First Sechenov Moscow State Medical University (Sechenov University); Niigata University

Email: eborzova@gmail.com
ORCID iD: 0000-0003-1587-9137

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow; Niigata, Japan

Elena A. Vishneva

Pediatrics and Child Health Research Institute of Petrovsky National Research Centre of Surgery; The Russian National Research Medical University named after N.I. Pirogov

Email: vishneva.e@yandex.ru
ORCID iD: 0000-0001-7398-0562

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow; Moscow

Yulia A. Gallyamova

Russian Medical Academy of Continuous Professional Education

Email: derma2006@yandex.ru
ORCID iD: 0000-0002-1674-3007

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Inna V. Danilychevа

State Research Center of Dermatovenerology and Cosmetology

Author for correspondence.
Email: ivdanilycheva@mail.ru
ORCID iD: 0000-0002-8279-2173

MD, Dr. Sci. (Med.)

Russian Federation, Moscow

Olga G. Elisyutina

National Research Center--Institute of Immunology Federal Medical-Biological Agency of Russia; Peoples' Friendship University of Russia

Email: el-olga@yandex.ru
ORCID iD: 0000-0002-4609-2591

MD, Dr. Sci. (Med.)

Russian Federation, Moscow; Moscow

Lyudmila F. Znamenskaya

State Research Center of Dermatovenerology and Cosmetology

Email: znaml@cnikvi.ru
ORCID iD: 0000-0002-2553-0484

MD, Dr. Sci. (Med.)

Russian Federation, Moscow

Natalia I. Ilyina

National Research Center--Institute of Immunology Federal Medical-Biological Agency of Russia

Email: instimmun@yandex.ru
ORCID iD: 0000-0002-3556-969X

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Vera G. Kalugina

Pediatrics and Child Health Research Institute of Petrovsky National Research Centre of Surgery

Email: v-starikova@mail.ru
ORCID iD: 0000-0002-3781-8661

MD, Cand. Sci. (Med.), Associate Professor

Russian Federation, Moscow

Arfenya Е. Karamova

State Research Center of Dermatovenerology and Cosmetology

Email: karamova@cnikvi.ru
ORCID iD: 0000-0003-3805-8489

MD, Cand. Sci. (Med.), Associate Professor

Russian Federation, Moscow

Yulia G. Levina

The Russian National Research Medical University named after N.I. Pirogov

Email: julia.levina@mail.ru
ORCID iD: 0000-0002-2460-7718

MD, Cand. Sci. (Med.)

Russian Federation, Moscow

Raisa Y. Meshkova

Smolensk State University

Email: Meshkova.raisa@yandex.ru

MD, Dr. Sci. (Med.), Professor

Russian Federation, Smolensk

Olga Y. Olisova

The First Sechenov Moscow State Medical University (Sechenov University)

Email: olisova_o_yu@staff.sechenov.ru
ORCID iD: 0000-0003-2482-1754

MD, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences

Russian Federation, Moscow

Gennadiy A. Novik

Saint-Petersburg State Pediatric Medical University

Email: ga_novik@mail.ru
ORCID iD: 0000-0002-7571-5460

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

Aleksey V. Samtsov

Kirov Military Medical Academy

Email: rodv@cnikvi.ru
ORCID iD: 0000-0002-9458-0872

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

Liliya R. Selimzyanova

Pediatrics and Child Health Research Institute of Petrovsky National Research Centre of Surgery; The Russian National Research Medical University named after N.I. Pirogov; The First Sechenov Moscow State Medical University (Sechenov University)

Email: lilysir@mail.ru
ORCID iD: 0000-0002-3678-7939

MD, Cand. Sci. (Med.)

Russian Federation, Moscow; Moscow; Moscow

Evgeny V. Sokolovskiy

Academician I.P. Pavlov First St. Petersburg State Medical University

Email: s40@mail.ru
ORCID iD: 0000-0001-7610-6061

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

Elena S. Fedenko

National Research Center--Institute of Immunology Federal Medical-Biological Agency of Russia

Email: efedks@gmail.com
ORCID iD: 0000-0003-3358-5087

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Olga S. Fedorova

Siberian State Medical University

Email: osf77@list.ru
ORCID iD: 0000-0002-7130-9609

MD, Dr. Sci. (Med.), Professor

Russian Federation, Tomsk

Daria S. Fomina

The First Sechenov Moscow State Medical University (Sechenov University); Moscow City Hospital 52; Astana Medical University

Email: daria_fomina@mail.ru
ORCID iD: 0000-0002-5083-6637

MD, Cand. Sci. (Med.), Associate Professor

Russian Federation, Moscow; Moscow; Astana, Republic of Kazakhstan

Vladislav R. Khairutdinov

Kirov Military Medical Academy

Email: rodv@cnikvi.ru
ORCID iD: 0000-0002-0387-5481

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

Vadim V. Chikin

State Research Center of Dermatovenerology and Cosmetology

Email: chikin@cnikvi.ru
ORCID iD: 0000-0002-9688-2727

MD, Cand. Sci. (Med.)

Russian Federation, Moscow

Andrey Е. Shulzhenko

National Research Center--Institute of Immunology Federal Medical-Biological Agency of Russia

Email: shulzhenko_ae@mail.ru
ORCID iD: 0000-0003-0268-9350

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

References

  1. Federal clinical recommendations on the diagnosis and treatment of urticaria. Moscow: Russian Association of Allergists and Clinical Immunologists; 2015. 34 р. (In Russ).
  2. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–766. doi: 10.1111/all.15090
  3. Bracken SJ, Abraham S, MacLeod AS. Autoimmune theories of chronic spontaneous urticaria. Front Immunol. 2019;10:627. doi: 10.3389/fimmu.2019.00627
  4. Maurer M, Altrichter S, Schmetzer O, et al. Immunoglobulin E-mediated autoimmunity. Front Immunol. 2018;9:689. doi: 10.3389/fimmu.2018.00689
  5. Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: What we know and what we do not know. J Allergy Clin Immunol. 2017;139(6):1772–1781.e1. doi: 10.1016/j.jaci.2016.08.050
  6. Vonakis BM, Vasagar K, Gibbons SP Jr, et al. Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. J Allergy Clin Immunol. 2007;119(2):441–448. doi: 10.1016/j.jaci.2006.09.035
  7. Luquin E, Kaplan AP, Ferrer M. Increased responsiveness of basophils of patients with chronic urticaria to sera but hypo- responsiveness to other stimuli. Clin Exp Allergy. 2005;35(4):456–460. doi: 10.1111/j.1365-2222.2005.02212.x
  8. Gibbs BF, Räthling A, Zillikens D, et al. Initial Fc epsilon RI-mediated signal strength plays a key role in regulating basophil signaling and deactivation. J Allergy Clin Immunol. 2006;118(5):1060–1067. doi: 10.1016/j.jaci.2006.07.022
  9. Maurer M, Church MK, Gonçalo M, et al. Management and treatment of chronic urticaria (CU). J Eur Acad Dermatol Venereol. 2015;29(3):16–32. doi: 10.1111/jdv.13198
  10. Greenberger PA. Chronic urticaria: New management options. World Allergy Organ J. 2014;7(1):31. doi: 10.1186/1939-4551-7-31
  11. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270–1277. doi: 10.1016/j.jaci.2014.02.036
  12. Pite H, Wedi B, Borrego LM, et al. Management of childhood urticaria: Current knowledge and practical recommendations. Acta Derm Venereol. 2013;93(5):500–508. doi: 10.2340/00015555-1573
  13. Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy. 2011;66(3):317–330. doi: 10.1111/j.1398-9995.2010.02496.x
  14. Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy. 2020;75(2):423–432. doi: 10.1111/all.14037
  15. Saini S, Shams M, Bernstein JA, Maurer M. Urticaria and angioedema across the ages. J Allergy Clin Immunol Pract. 2020;8(6):1866–1874. doi: 10.1016/j.jaip.2020.03.0302-6
  16. Goldstein S, Gabriel S, Kianifard F, et al. Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: Review of omalizumab clinical trials. Ann Allergy Asthma Immunol. 2017;118(4):500–504. doi: 10.1016/j.anai.2017.02.0035
  17. Curto-Barredo L, Pujol RM, Roura-Vives G, Gimenez-Arnau AM. Chronic urticaria phenotypes: Clinical differences regarding triggers, activity, prognosis and therapeutic response. Eur J Dermatol. 2019;29(6):627–635. doi: 10.1684/ejd.2019.36746
  18. Netchiporouk E, Sasseville D, Moreau L, et al. Evaluating comorbidities, natural history, and predictors of early resolution in a cohort of children with chronic urticaria. JAMA Dermatol. 2017;153(12):1236–1242. doi: 10.1001/jamadermatol.2017.3182
  19. Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med. 2002;346(3):175–179. doi: 10.1056/NEJMcp011186
  20. Caffarelli C, Paravati F, El Hachem M, et al. Management of chronic urticaria in children: A clinical guideline. Ital J Pediatr. 2019;45(1):101. doi: 10.1186/s13052-019-0695-x.
  21. Toubi E, Kessel A, Avshovich N, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: A prospective study of 139 patients. Allergy. 2004;59(8):869–873. doi: 10.1111/j.1398-9995.2004.00473.x
  22. Schoepke N, Doumoulakis G, Maurer M. Diagnosis of urticaria. Indian J Dermatol. 2013;58(3):211–218. doi: 10.4103/0019-5154.110831
  23. Namazova-Baranova LS. Allergy in children: From theory to practice. Moscow: Russian Paediatric Union; 2010-2011. 668 р. (In Russ).
  24. Nettis E, Foti C, Ambrifi M, et al. Urticaria: Recommendations from the Italian Society of Allergology, Asthma and Clinical Immunology and the Italian Society of Allergological, Occupational and Environmental Dermatology. Clin Mol Allergy. 2020;18:8. doi: 10.1186/s12948-020-00123-8
  25. Metz M, Altrichter S, Buttgereit T, et al. The diagnostic workup in chronic spontaneous urticaria--What to test and why. J Allergy Clin Immunol Pract. 2021;9(6):2274–2283. doi: 10.1016/j.jaip.2021.03.049
  26. Kolkhir P, André F, Church MK, et al. Potential blood biomarkers in chronic spontaneous urticaria. Clin Exp Allergy. 2017;47(1):19–36. doi: 10.1111/cea.12870
  27. Altrichter S, Fok JS, Jiao Q, et al. Total IgE as a marker for chronic spontaneous urticaria. Allergy Asthma Immunol Res. 2021;13(2):206–218. doi: 10.4168/aair.2021.13.2.206
  28. Fok JS, Kolkhir P, Church MK, Maurer M. Predictors of treatment response in chronic spontaneous urticaria. Allergy. 2021;76(10):2965–2981. doi: 10.1111/all.14757
  29. Kolkhir P, Altrichter S, Asero R, et al. Autoimmune diseases are linked to type iib autoimmune chronic spontaneous urticaria. Allergy Asthma Immunol Res. 2021;13(4):545–559. doi: 10.4168/aair.2021.13.4.545
  30. Cornillier H, Giraudeau B, Munck S, et al. Chronic spontaneous urticaria in children--a systematic review on interventions and comorbidities. Pediatr Allergy Immunol. 2018;29(3):303–310. doi: 10.1111/pai.12870
  31. Spickett G. Urticaria and angioedema. J R Coll Physicians Edinb. 2014;44(1):50–54. doi: 10.4997/JRCPE.2014.112
  32. Kolkhir P, Balakirski G, Merk HF, et al. Chronic spontaneous urticaria and internal parasites--a systematic review. Allergy. 2016;71(3):308–322. doi: 10.1111/all.12818
  33. Minciullo PL, Cascio A, Gangemi S. Association between urticaria and nematode infections. Allergy Asthma Proc. 2018;39(2):86–95. doi: 10.2500/aap.2018.38.4104
  34. Fedorova OS, Fedotova MM, Zvonareva OI, et al. Opisthorchis felineus infection, risks, and morbidity in rural Western Siberia, Russian Federation. PLoS Negl Trop Dis. 2020;14(6):e0008421. doi: 10.1371/journal.pntd.0008421
  35. Sayasone S, Odermatt P, Phoumindr N, et al. Epidemiology of Opisthorchis viverrini in a rural district of southern Lao PDR. Trans R Soc Trop Med Hyg. 2007;101(1):40–47. doi: 10.1016/j.trstmh.2006.02.018
  36. Neumayr A. Antiparasitic treatment recommendations. A practical guide to clinical parasitology. Publisher: Tredition; 2016. 173 p.
  37. Ataseven A, Durmaz K, Ozer I, Dursun R. Gallstones at chronic spontaneous urticaria patients: A retrospective clinical study. Dermatol Ther. 2020;33(2):e13212. doi: 10.1111/dth.13212
  38. Minciullo PL, Cascio A, Barberi G, Gangemi S. Urticaria and bacterial infections. Allergy Asthma Proc. 2014;35(4):295–302. doi: 10.2500/aap.2014.35.3764
  39. Imbalzano E, Casciaro M, Quartuccio S, et al. Association between urticaria and virus infections: A systematic review. Allergy Asthma Proc. 2016;37(1):18–22. doi: 10.2500/aap.2016.37.3915
  40. Sugrañes-Montalván A, Barreto-Suárez E, Nicolau-Pestana E, Quesada-Leyva L. Relación entre infección por Helicobacter pylori y urticaria crónica [Relation between Helicobacter pylori infection and chronic urticaria]. Rev Alerg Mex. 2017;64(4):396–402. doi: 10.29262/ram.v64i4.283
  41. Kim HJ, Kim YJ, Lee HJ, et al. Systematic review and meta-analysis: Effect of Helicobacter pylori eradication on chronic spontaneous urticaria. Helicobacter. 2019;24(6):e12661. doi: 10.1111/hel.12661
  42. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema--the 2017 revision and update. Allergy. 2018;73(8):1575–1596. doi: 10.1111/all.13384
  43. Сaballero T, Baeza ML, Cabañas R, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations [published correction appears in J Investig Allergol Clin Immunol. 2012;22(2):3, following 153]. J Investig Allergol Clin Immunol. 2011;21(6):422–443.
  44. Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: Consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69(5):602–616. doi: 10.1111/all.12380
  45. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6(1):24. doi: 10.1186/1710-1492-6-24
  46. Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: Problems and progress. Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(3 Suppl):S51–S131. doi: 10.1016/j.jaci.2004.06.047
  47. Peroni A, Colato C, Schena D, Girolomoni G. Urticarial lesions: If not urticaria, what else? The differential diagnosis of urticaria: Part 1. Cutaneous diseases. J Am Acad Dermatol. 2010;62:541–555. doi: 10.1016/j.jaad.2009.11.686
  48. Niu XL, Zhu LL, Shi MH, et al. Association of positive and negative autologous serum skin test responses with clinical features of chronic spontaneous urticaria in Asian patients: A systematic review and meta-analysis. Exp Ther Med. 2019;17(4):2603–2613. doi: 10.3892/etm.2019.7266
  49. Kulthanan K, Subchookul C, Hunnangkul S, et al. Factors predicting the response to cyclosporin treatment in patients with chronic spontaneous urticaria: A systematic review. Allergy Asthma Immunol Res. 2019;11(5):736–755. doi: 10.4168/aair.2019.11.5.736
  50. George M, Balachandran C, Prabhu S. Chronic idiopathic urticaria: Comparison of clinical features with positive autologous serum skin test. Indian J Dermatol Venereol Leprol. 2008;74(2):105–108. doi: 10.4103/0378-6323.39690
  51. Khan DA. Chronic spontaneous urticaria: Standard management and patient education [2022 Dec 21]. Available from: https://www.uptodate.com/contents/chronic-spontaneous-urticaria-standard-management-and-patient-education?search=urticaria&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2. Accessed: 15.01.2024.
  52. Cicardi M, Bellis P, Bertazzoni G, et al. Guidance for diagnosis and treatment of acute angioedema in the emergency department: Consensus statement by a panel of Italian experts. Intern Emerg Med. 2014;9(1):85–92. doi: 10.1007/s11739-013-0993-z
  53. Depetri F, Tedeschi A, Cugno M. Angioedema and emergency medicine: From pathophysiology to diagnosis and treatment. Eur J Intern Med. 2019;59:8–13. doi: 10.1016/j.ejim.2018.09.004
  54. Adeyeni TA, Domack A, Britt C. What is the role of laryngoscopy in angioedema isolated to the lips, without laryngeal symptoms? Laryngoscope. 2020;130(12):2740–2741. doi: 10.1002/lary.28664
  55. Weller K, Groffik A, Magerl M, et al. Development, validation, and initial results of the Angioedema Activity Score. Allergy. 2013;68(9):1185–1192. doi: 10.1111/all.12209
  56. Shikiar R, Harding G, Leahy M, Lennox RD. Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): Results from patients with chronic idiopathic urticaria. Health Qual Life Outcomes. 2005;3:36. doi: 10.1186/1477-7525-3-36
  57. Prosty C, Gabrielli S, Mule P, et al. Validation of the Urticaria Control Test (UCT) in children with chronic urticaria. J Allergy Clin Immunol Pract. 2022;10(12):3293–3298.e2. doi: 10.1016/j.jaip.2022.07.037
  58. Młynek A, Zalewska-Janowska A, Martus P, et al. How to assess disease activity in patients with chronic urticaria? Allergy. 2008;63(6):777–780. doi: 10.1111/j.1398-9995.2008.01726.x
  59. Patruno C, Napolitano M, Ferrucci S, et al. Four-week Urticaria Activity Score-7 as a useful patient-reported outcome to assess chronic spontaneous urticaria: A multicentre study evaluation of adherence and patients' perspective. Acta Derm Venereol. 2019;99(10):903–904. doi: 10.2340/00015555-3231
  60. Borzova ЕY, Salugina CO. Current problems in the differential diagnosis of urticaria. Effective pharmacotherapy. 2017;(7):34–45. EDN: YGGKFN
  61. Soter NA. Chronic urticaria as a manifestation of necrotizing venulitis. N Engl J Med. 1977;296:1440–1442.
  62. Kolhir,П. V. Urticarial vasculitis: a modern approach to diagnosis and treatment / P. V. Kolhir, O. Yu.Kolhir, O. Y. Olisova // Lechaschichnyi doktor. 2015;(11): 20. - EDN VCLOIN.
  63. Brodell LA, Beck LA. Differential diagnosis of chronic urticaria. Ann Allergy Asthma Immunol. 2008;100(3):181–215. doi: 10.1016/S1081-1206(10)60438-3
  64. Makhneva NV. Modern view on the diagnosis and treatment of bullous dermatoses. International journal of applied and fundamental research. 2011;(9):15–17. (In Russ). EDN: NYGJOX
  65. Banchenko GV, Fleischer GM, Gorin AA. Experience of treatment of erythema multiforme exudative. Medical Alphabet. 2013;1(1):44–46. (In Russ). EDN: PWHFWN
  66. Patel S, Patel R, Draikiwicz S, Capitle E. Peripheral T-cell lymphoma: A challenging mimicker of angioedema and urticaria. Ann Allergy Asthma Immunol. 2015;115(2):94–95. doi: 10.1016/j.anai.2015.06.013
  67. Brockow K. Urticaria pigmentosa. Immunol Allergy Clin North Am. 2004;24(2):287-vii. doi: 10.1016/j.iac.2004.01.002
  68. Khaliulin YG. Mastocytosis: Clinical manifestations, diagnostic methods and tactics of patient management. Lechachashchy doctor. 2012;(8):83–89. (In Russ). EDN: SITJPP
  69. Mukhin N, Moiseev C, Popova E, et al. Late manifestations of Lyme disease. Vrach. 2006;(5):35–38. (In Russ). EDN: KXXVLL
  70. Kochergin N, Nikitina E, Tsykin A. Some features of pregnancy dermatoses. Vrach. 2010;(1):51–55. EDN: KYVXQZ
  71. Novikov DK, Sergeev YV, Novikov PD, Sergeev AYu. Adverse allergic reactions on drugs and other preparations in dermathology. Immunopathology, allergology, infectology. 2003;(3):45–67. EDN: RVFIKX
  72. Foer D, Buchheit KM, Gargiulo AR, et al. Progestogen hypersensitivity in 24 cases: diagnosis, management, and proposed renaming and classification. J Allergy Clin Immunol Pract. 2016;4(4):723–729. doi: 10.1016/j.jaip.2016.03.003
  73. Antonova OV, Trofimov PN, Belousova IE, Samtsov AV. Reticular erythematous mucinosis. Vestnik dermatologii i venerologii. 2014;(5):96–99. EDN: TGDMHH
  74. Kolkhir P, Pogorelov D, Olisova O, Maurer M. Comorbidity and pathogenic links of chronic spontaneous urticaria and systemic lupus erythematosus--a systematic review. Clin Exp Allergy. 2016;46(2):275–287. doi: 10.1111/cea.12673
  75. Khamaganova I.V. Difficulties in diagnosing various forms of lupus erythematosus. Klinitsist. 2006;1(1):64–68. EDN: LSPZKP
  76. Kuzmina NN, Salugina CO, Fedorov EC. Autoinflammatory diseases and syndromes in children: Educational and methodological manual. Moscow: IMA-PRESS; 2012. 104 р. (In Russ).
  77. Barron K, Athreya B, Kastner D. Periodic fever syndromes and other inherited autoinflammatory diseases. In: Textbook of pediatric rheumatology. Ed. by J.T. Cassidy, R.E. Petty. 7th ed. Elsevier Saunders; 2015. P. 609–641.
  78. Toplak N, Frenkel J, Ozen S, et al. An international registry on autoinflammatory diseases: The Eurofever experience. Ann Rheum Dis. 2012;71(7):1177–1182. doi: 10.1136/annrheumdis-2011-200549
  79. Simon A, Asli B, Braun-Falco M, et al. Schnitzler's syndrome: Diagnosis, treatment, and follow-up. Allergy. 2013;68(5):562–568. doi: 10.1111/all.12129
  80. De Castro FR, Masouye I, Winkelmann RK, Saurat JH. Urticarial pathology in Schnitzler’s (hyper-IgM) syndrome. Dermatology. 1996;193(2):94–99.
  81. Znamenskaya LF, Osokina DE, Vavilov AM. Sweet's syndrome. Vestnik dermatologii i venerologii. 2008;(2):94–96. EDN: IJUJSZ
  82. Butterfield JH. Flushing and urticarial syndromes presenting as anaphylaxis. In book: Anaphylaxis and hypersensitivity reactions. Springer; 2010. P. 271–284. doi: 10.1007/978-1-60327-951-2_17
  83. Heger PG. Paediatric dermatology. Moscow: Izdatel'stvo Panfilova/Binom. Laboratoriya znanii; 2013. 634 р. (In Russ).
  84. Allergology and immunology (Practical recommendations for paediatricians). Ed. by A.A. Baranov, R.M. Khaitov. Moscow: Union of Paediatricians of Russia; 2020. 512 р. (In Russ).
  85. Hocqueloux L, Guinard J, Buret J, et al. Do penicillins really increase the frequency of a rash when given during Epstein-Barr Virus primary infection? Clin Infect Dis. 2013;57(11):1661–1662. doi: 10.1093/cid/cit553
  86. Dibek Misirlioglu E, Guvenir H, Ozkaya Parlakay A, et al. Incidence of antibiotic-related rash in children with Epstein-Barr Virus Infection and evaluation of the frequency of confirmed antibiotic hypersensitivity. Int Arch Allergy Immunol. 2018;176(1):33–38. doi: 10.1159/000481988
  87. Kowalski ML, Woessner K, Sanak M. Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug-related urticaria and angioedema. J Allergy Clin Immunol. 2015;136(2):245–251. doi: 10.1016/j.jaci.2015.06.021
  88. Shakouri A, Compalati E, Lang DM, Khan DA. Effectiveness of Helicobacter pylori eradication in chronic urticaria: Evidence-based analysis using the grading of recommendations assessment, development, and evaluation system. Curr Opin Allergy Clin Immunol. 2010;10(4):362–369. doi: 10.1097/ACI.0b013e32833c79d7
  89. Ishaq S, Nunn L. Helicobacter pylori and gastric cancer: A state of the art review. Gastroenerol Hepatol Bed Bench. 2015;8(l1):6–14.
  90. Arik Yilmaz E, Karaatmaca B, Sackesen C, et al. Parasitic infections in children with chronic spontaneous urticaria. Int Arch Allergy Immunol. 2016;171(2):130–135. doi: 10.1159/000450953
  91. Zuberbier T, Chantraine Kess S, Hartmann K, Czarnetzki BM. Pseudoallergen-free diet in the treatment of chronic urticaria--a prospective study. Acta Derm Venereol. 1995;75:484–487.
  92. Cornillier H, Giraudeau B, Samimi M, et al. Effect of diet in chronic spontaneous urticaria: A systematic review. Acta Derm Venereol. 2019;99(2):127–132. doi: 10.2340/00015555-3015
  93. Nettis E, Colanardi MC, Ferrannini A, Tursi A. Sodium benzoate-induced repeated episodes of acute urticaria/angio-oedema: Randomized controlled trial. Br J Dermatol. 2004;151(4):898–902. doi: 10.1111/j.1365-2133.2004.06095.x
  94. Akoglu G, Atakan N, Cakır B, et al. Effects of low pseudoallergen diet on urticarial activity and leukotriene levels in chronic urticaria. Arch Dermatol Res. 2012;304(4):257–262. doi: 10.1007/s00403-011-1203-3
  95. Son JH, Chung BY, Kim HO, Park CW. A histamine-free diet is helpful for treatment of adult patients with chronic spontaneous urticaria. Ann Dermatol. 2018;30(2):164–172. doi: 10.5021/ad.2018.30.2.164
  96. Sánchez-Pérez S, Comas-Basté O, Veciana-Nogués MT, et al. Low-histamine diets: Is the exclusion of foods justified by their histamine content? Nutrients. 2021;13(5):1395. doi: 10.3390/nu13051395
  97. Allergology. Federal clinical recommendations. Ed. by R.M. Khaitov, N.I. Ilyina. Moscow: Pharmarus Print Media; 2014. 126 р. (In Russ).
  98. Beissert S, Ständer H, Schwarz T. UVA rush hardening for the treatment of solar urticaria. J Am Acad Dermatol. 2000;42(6):1030–1032. doi: 10.1016/s0190-9622(00)90299-8
  99. Kring Tannert L, Stahl Skov P, Bjerremann Jensen L, et al. Cold urticaria patients exhibit normal skin levels of functional mast cells and histamine after tolerance induction. Dermatology. 2012;224(2):101–105. doi: 10.1159/000336572
  100. Sharma M, Bennett C, Cohen SN, Carter B. H1-antihistamines for chronic spontaneous urticaria. Cochrane Database Syst Rev. 2014;2014(11):CD006137. doi: 10.1002/14651858.CD006137
  101. Williams PV. Pharmacologic management of chronic urticaria in pediatric patients: The gap between guidelines and practice. Paediatr Drugs. 2020;22(1):21–28. doi: 10.1007/s40272-019-00365-3
  102. Kudryavtseva AV, Neskorodova KA, Staubach P. Urticaria in children and adolescents: An updated review of the pathogenesis and management. Pediatr Allergy Immunol. 2019;30(1):17–24. doi: 10.1111/pai.12967
  103. Nakamura T, Hiraoka K, Harada R, et al. Brain histamine H1 receptor occupancy after oral administration of desloratadine and loratadine. Pharmacol Res Perspect. 2019;7(4):e00499. doi: 10.1002/prp2.499
  104. Haria M, Fitton A, Peters DH. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs. 1994;48(4):617–637. doi: 10.2165/00003495-199448040-00009
  105. An overview of angioedema: Clinical features, diagnosis, and management [2022 Dec 21]. Available from: https://www.uptodate.com/contents/an-overview-of-angioedema-clinical-features-diagnosis-and-management?search=urticaria&topicRef=8108&source=related_link. Accessed: 15.01.2024.
  106. Federal clinical recommendations "Anaphylactic shock". Moscow: Russian Association of Allergologists and Clinical Immunologists, Federation of Anaesthesiologists and Resuscitators; 2022. (In Russ).
  107. Zuberbier T, Iffländer J, Semmler C, Henz BM. Acute urticaria: Clinical aspects and therapeutic responsiveness. Acta Derm Venereol. 1996;76(4):295–297. doi: 10.2340/0001555576295297
  108. Asero R, Tedeschi A. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: A retrospective analysis. J Investig Allergol Clin Immunol. 2010;20(5):386–390.
  109. Talarico V, Marseglia GL, Lanari M, et al. Pediatric urticaria in the Emergency Department: Epidemiological characteristics and predictive factors for its persistence in children. Eur Ann Allergy Clin Immunol. 2021;53(2):80–85. doi: 10.23822/EurAnnACI.1764-1489.148
  110. Long BJ, Koyfman A, Gottlieb M. Evaluation and management of angioedema in the emergency department. West J Emerg Med. 2019;20(4):587–600. doi: 10.5811/westjem.2019.5.42650
  111. Agache I, Rocha C, Pereira A, et al. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines. Allergy. 2021;76(1):59–70. doi: 10.1111/all.14547
  112. Aleksandraviciute L, Malinauskiene L, Cerniauskas K, Chomiciene A. Plasmapheresis: Is it a potential alternative treatment for chronic urticaria? Open Med (Wars). 2021;17(1):113–118. doi: 10.1515/med-2021-0399
  113. Altrichter S, Salow J, Ardelean E, et al. Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria. J Dermatol Sci. 2014;75(2):88–93. doi: 10.1016/j.jdermsci.2014.04.007
  114. Lee EE, Maibach HI. Treatment of urticaria. An evidence-based evaluation of antihistamines. Am J Clin Dermatol. 2001;2(1):27–32. doi: 10.2165/00128071-200102010-00005
  115. Grob JJ, Auquier P, Dreyfus I, Ortonne JP. How to prescribe antihistamines for chronic idiopathic urticaria: Desloratadine daily vs PRN and quality of life. Allergy. 2009;64(4):605–612. doi: 10.1111/j.1398-9995.2008.01913.x
  116. Weller K, Ardelean E, Scholz E, et al. Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study. Acta Derm Venereol. 2013;93(2):168–174. doi: 10.2340/00015555-1434
  117. Murota H, Kitaba S, Tani M, et al. Impact of sedative and non-sedative antihistamines on the impaired productivity and quality of life in patients with pruritic skin diseases. Allergol Int. 2010;59(4):345–354. doi: 10.2332/allergolint.10-OA-0182
  118. Fein MN, Fischer DA, O'Keefe AW, Sussman GL. CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria. Allergy Asthma Clin Immunol. 2019;15:61. doi: 10.1186/s13223-019-0375-9
  119. Chu DK, Oykhman P, Sussman GL. How to use antihistamines. CMAJ. 2021;193(14):E478–E479. doi: 10.1503/cmaj.201959
  120. Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125:676–682.
  121. Siebenhaar F, Degener F, Zuberbier T, et al. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: A randomized, placebo-controlled, crossover study. J Allergy Clin Immunol. 2009;123(3):672–679. doi: 10.1016/j.jaci.2008.12.008
  122. Giménez-Arnau A, Izquierdo I, Maurer M. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo--controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol. 2009;23(9):1088–1091. doi: 10.1111/j.1468-3083.2009.03289.x
  123. Phinyo P, Koompawichit P, Nochaiwong S, et al. Comparative efficacy and acceptability of licensed dose second-generation antihistamines in chronic spontaneous urticaria: A network meta-analysis. J Allergy Clin Immunol Pract. 2021;9(2):956–970.e57. doi: 10.1016/j.jaip.2020.08.055
  124. Iriarte Sotés P, Armisén M, Usero-Bárcena T, et al.; Urtigal, the Galician Group of Interest in Urticaria. Efficacy and safety of up-dosing antihistamines in chronic spontaneous urticaria: A systematic review of the literature. J Investig Allergol Clin Immunol. 2021;31(4):282–291. doi: 10.18176/jiaci.0649
  125. Guillén-Aguinaga S, Jáuregui Presa I, Aguinaga-Ontoso E, et al. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: A systematic review and meta-analysis. Br J Dermatol. 2016;175(6):1153–1165. doi: 10.1111/bjd.14768
  126. Church MK, Tiongco-Recto M, Ridolo E, Novák Z. Bilastine: A lifetime companion for the treatment of allergies. Curr Med Res Opin. 2020;36(3):445–454. doi: 10.1080/03007995.2019.1681134
  127. Kontou-Fili K, Maniatakou G, Demaka P, et al. Therapeutic effects of cetirizine in delayed pressure urticaria: clinicopathologic findings. J Am Acad Dermatol. 1991;24(6 Pt 2):1090–1093. doi: 10.1016/0190-9622(91)70163-v
  128. Zuberbier T, Münzberger C, Haustein U, et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology. 1996;193(4):324–327. doi: 10.1159/000246281
  129. Zhang L, Wu J, Qi Y, et al. Long-term combinations and updosing of second-generation H1-antihistamines show efficacy and safety in the treatment of chronic spontaneous urticaria: A multicenter real-life pilot study. J Allergy Clin Immunol Pract. 2020;8(5):1733–1736.e11. doi: 10.1016/j.jaip.2019.12.006
  130. Sarti L, Barni S, Giovannini M, et al. Efficacy and tolerability of the updosing of second-generation non-sedating H1 antihistamines in children with chronic spontaneous urticaria. Pediatr Allergy Immunol. 2021;32(1):153–160. doi: 10.1111/pai.13325
  131. Koosakulchai V, Yuenyongviwat A, Sangsupawanich P. Risk factors of uncontrolled symptoms using the standard dose of second-generation H1-antihistamines in chronic spontaneous urticaria children. Asian Pac J Allergy Immunol. 2022;40(2):121–125.
  132. Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742–1750.e4. doi: 10.1016/j.jaci.2015.12.1342
  133. Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence. J Allergy Clin Immunol. 2018;141(2):638–649. doi: 10.1016/j.jaci.2017.06.032
  134. Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: A meta-analysis of "real-world" evidence. JAMA Dermatol. 2019;155(1):29–38. doi: 10.1001/jamadermatol.2018.3447
  135. Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128(3):567–573.e1. doi: 10.1016/j.jaci.2011.06.010
  136. Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128(1):202–209.e5. doi: 10.1016/j.jaci.2011.04.038
  137. Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study [published correction appears in J Invest Dermatol. 2015;135(3):925]. J Invest Dermatol. 2015;135(1):67–75. doi: 10.1038/jid.2014.306
  138. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria [published correction appears in N Engl J Med. 2013;368(24):2340–2341]. N Engl J Med. 2013;368(10):924–935. doi: 10.1056/NEJMoa1215372
  139. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101–109. doi: 10.1016/j.jaci.2013.05.013
  140. Urgert MC, van den Elzen MT, Knulst AC, et al. Omalizumab in patients with chronic spontaneous urticaria: A systematic review and GRADE assessment. Br J Dermatol. 2015;173(2):404–415. doi: 10.1111/bjd.13845
  141. Rubini NP, Ensina LF, Silva EM, et al. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis. Allergol Immunopathol (Madr). 2019;47(6):515–522. doi: 10.1016/j.aller.2019.05.003
  142. Jia HX, He YL. Efficacy and safety of omalizumab for chronic spontaneous urticaria: A systematic review and meta-analysis of randomized controlled trials. Am J Ther. 2020;27(5):e455–e467. doi: 10.1097/MJT.0000000000000912
  143. Summary of Product Characteristics--Xolair (omalizumab). Novartis Europharm Limited [2022 Dec 21]. Available from: https://www.ema.europa.eu/en/documents/product-information/xolair-epar-productinformation_en.pdf. Accessed: 15.01.2024.
  144. Kocatürk E, Deza G, Kızıltaç K, Giménez-Arnau AM. Omalizumab updosing for better disease control in chronic spontaneous urticaria patients. Int Arch Allergy Immunol. 2018;177(4):360–364. doi: 10.1159/000491530
  145. Metz M, Vadasz Z, Kocatürk E, Giménez-Arnau AM. Omalizumab updosing in chronic spontaneous urticaria: An overview of real-world evidence. Clin Rev Allergy Immunol. 2020;59(1):38–45. doi: 10.1007/s12016-020-08794-6
  146. Manzoor H, Razi F, Rasheed A, et al. Efficacy of different dosing regimens of ige targeted biologic omalizumab for chronic spontaneous urticaria in adult and pediatric populations: A meta-analysis. Healthcare (Basel). 2022;10(12):2579. doi: 10.3390/healthcare10122579
  147. Staubach P, Peveling-Oberhag A, Lang BM et al. Severe chronic spontaneous urticaria in children: Treatment options according to the guidelines and beyond--a 10 years review. J Dermatolog Treat. 2022;33(2

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Appendix A3.4. Algorithm for differential diagnosis of diseases, accompanied by the presence of blisters and/or angioedema (adapted from [2])

Download (297KB)
Indexing metadata
3. Appendix B1. Treatment algorithm for a patient with chronic urticaria (adapted from [2])

Download (213KB)
Indexing metadata

Copyright (c) 2024 Pharmarus Print Media

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies